Cytochrome P450 Enzyme System: Genetic Polymorphisms and Impact on Clinical Pharmacology
Open Access
- 1 November 1999
- journal article
- review article
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 36 (6) , 722-729
Abstract
The cytochrome P450 (CYP) enzyme system is involved in the metabolism and elimination of numerous widely used drugs. The capacity of this system varies from one person to another, leading to variable drug excretion rates and intersubject differences in the final serum drug concentrations. For this reason, therapeutic response and side-effects vary widely between patients treated with the same dose of drug. The intersubject variability in metabolic rate is largely determined by genetic factors. Some CYP enzymes, including CYP2D6 and CYP2C19, are genetically polymorphic. Several mutant alleles have been described. Environmental factors such as smoking, diet and co-administration of medications might also influence the CYP enzyme activity. By the use of genotyping or phenotyping methods every individual can be classified as either a poor, an intermediate, an extensive or an ultrarapid metabolizer. If this could be performed prior to drug therapy, the knowledge could be applied to drug selection and dose adjustment in order to reach therapeutic serum drug levels.Keywords
This publication has 45 references indexed in Scilit:
- Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype??Pharmacogenetics, 1996
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- “It's the genes, stupid” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphismLife Sciences, 1995
- Genetic Differences in Drug DispositionThe Journal of Clinical Pharmacology, 1994
- Assessment of Liver Metabolic FunctionClinical Pharmacokinetics, 1994
- Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotypeHuman Molecular Genetics, 1994
- Pharmacogenetic Phenotyping and GenotypingClinical Pharmacokinetics, 1994
- Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean populationPharmacogenetics, 1993
- Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolismPharmacogenetics, 1993
- P450 EnzymesClinical Pharmacokinetics, 1992